Skip to main content
Telix Pharmaceuticals Limited (ASX:TLX)
Australia flag Australia · Delayed Price · Currency is AUD
10.20
-0.55 (-5.12%)
At close: Mar 9, 2026

Telix Pharmaceuticals Revenue

In the year 2025, Telix Pharmaceuticals had annual revenue of $803.79M USD with 55.61% growth. Telix Pharmaceuticals had revenue of $413.44M in the half year ending December 31, 2025, with 115.29% growth.

Revenue
$803.79M
Revenue Growth
+55.61%
P/S Ratio
2.87
Revenue / Employee
$678.88K
Employees
1,184
Market Cap
3.46B AUD

Revenue Chart

* This company reports financials in USD.

History

Fiscal Year End Revenue Change Growth
Dec 31, 2025803.79M287.24M55.61%
Dec 31, 2024516.55M183.57M55.13%
Jan 1, 2024332.98M224.17M206.01%
Dec 31, 2022108.81M103.29M1,870.12%
Dec 31, 20215.52M1.50M37.33%
Dec 31, 2020 Pro Pro Pro
Dec 31, 2019 Pro Pro Pro
Dec 31, 2018 Pro Pro Pro
Dec 31, 2017 Pro Pro Pro
Dec 31, 2016 Pro Pro Pro

Revenue Definition

Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.

Full Definition

Related Stocks

Company Name Revenue
Mesoblast 98.02M
Neuren Pharmaceuticals 64.65M
PYC Therapeutics 20.56M
Clarity Pharmaceuticals 10.58M
Opthea -20.12K
Immutep 7.92M
Clinuvel Pharmaceuticals 96.30M
Racura Oncology 3.48M
Revenue Rankings

Telix Pharmaceuticals News

More News